Chemours Company (The) (NYSE:CC) SVP David C. Shelton sold 19,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $53.68, for a total value of $1,019,920.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

David C. Shelton also recently made the following trade(s):

  • On Thursday, August 31st, David C. Shelton sold 13,337 shares of Chemours Company (The) stock. The shares were sold at an average price of $48.48, for a total value of $646,577.76.

Shares of Chemours Company (NYSE CC) traded up 2.66% during trading on Thursday, reaching $54.43. The company had a trading volume of 1,740,010 shares. The firm has a market capitalization of $10.06 billion, a P/E ratio of 35.62 and a beta of 3.59. Chemours Company has a 12 month low of $14.41 and a 12 month high of $54.47. The firm’s 50 day moving average price is $51.28 and its 200 day moving average price is $51.28.

Chemours Company (The) (NYSE:CC) last announced its earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.02. The firm had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. Chemours Company (The)’s quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.27 EPS. Equities analysts predict that Chemours Company will post $3.51 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Thursday, August 17th were issued a dividend of $0.03 per share. This represents a $0.12 dividend on an annualized basis and a yield of 0.22%. The ex-dividend date was Tuesday, August 15th. Chemours Company (The)’s dividend payout ratio (DPR) is presently 8.11%.

TRADEMARK VIOLATION NOTICE: “Chemours Company (The) (CC) SVP Sells $1,019,920.00 in Stock” was published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/05/chemours-company-the-cc-svp-sells-1019920-00-in-stock.html.

Several equities analysts have recently weighed in on CC shares. Zacks Investment Research upgraded Chemours Company (The) from a “hold” rating to a “strong-buy” rating and set a $51.00 target price on the stock in a research report on Friday, July 14th. BidaskClub downgraded Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Saturday, June 17th. Jefferies Group LLC restated a “buy” rating and issued a $48.00 target price on shares of Chemours Company (The) in a research report on Friday, June 16th. Citigroup Inc. raised their target price on Chemours Company (The) from $45.00 to $59.00 and gave the company a “buy” rating in a research report on Friday, August 4th. Finally, J P Morgan Chase & Co raised their target price on Chemours Company (The) to $55.00 and gave the company an “overweight” rating in a research report on Friday, August 4th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $52.75.

A number of large investors have recently made changes to their positions in CC. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Chemours Company (The) during the 1st quarter valued at $450,000. Stifel Financial Corp grew its holdings in Chemours Company (The) by 6.3% during the 1st quarter. Stifel Financial Corp now owns 19,401 shares of the specialty chemicals company’s stock valued at $749,000 after buying an additional 1,146 shares during the last quarter. Cipher Capital LP acquired a new stake in Chemours Company (The) during the 1st quarter valued at $320,000. Victory Capital Management Inc. acquired a new stake in Chemours Company (The) during the 1st quarter valued at $6,461,000. Finally, Schroder Investment Management Group acquired a new stake in Chemours Company (The) during the 1st quarter valued at $156,000. Hedge funds and other institutional investors own 72.90% of the company’s stock.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Insider Buying and Selling by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.